Unknown PHASE1 INTERVENTIONAL 1-arm NCT05028933

IMC001 for Clinical Research on Advanced Digestive System Malignancies

Autologous T Cells Modified by Chimeric Antigen Receptor Targeting EpCAM for Clinical Research on Advanced Digestive System Malignancies

Sponsor: Zhejiang University

Conditions Advanced Colorectal Cancer Advanced Gastric Cancer Advanced Hepatocellular Carcinoma Advanced Pancreatic Cancer

Interventions EPCAM CAR-T

Updated 8 times since 2021 Last updated: Feb 8, 2024 Started: Sep 30, 2021 Primary completion: Dec 30, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Colorectal Cancer and Advanced Gastric Cancer and is currently ongoing. Zhejiang University leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Mar 2024 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

Feb 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Feb 2022 — Feb 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhejiang University

Data source: Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China
• Shanghai, China